Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Irinotecan + Pyrotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Pyrotinib||SHR-1258|SHR1258||EGFR Inhibitor (Pan) 55 HER2 Inhibitor 36||Pyrotinib is an irreversible dual inhibitor of EGFR and ERBB2 (HER2), which potentially leads to decreased growth of EGFR and/or HER2-positive tumor cells (PMID: 28115222, PMID: 30596880).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB3 V104L||gastric adenocarcinoma||predicted - sensitive||Irinotecan + Pyrotinib||Case Reports/Case Series||Actionable||In a clinical case study, combination treatment Camptosar (irinotecan) and Pyrotinib in a patient with metastatic gastric adenocarcinoma harboring ERBB3 V104L, who had relapsed on prior treatment with chemotherapy, led to stable disease and a progression-free survival of 7.6 months (PMID: 33500629).||33500629|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|